Souhaitez-vous accéder aux communiqués récents ?

AdRoll hits milestone as 200 brands activate Experian audiences across web & CTV—driving faster, smarter cross-channel campaigns with unified targeting.

NASHVILLE, Tenn., Oct. 07, 2025 (GLOBE NEWSWIRE) -- LBMC Physician Business Solutions, LLC (PBS), a member of the LBMC Family of Companies, is pleased to announce its expansion into the Memphis...

CALGARY, Alberta, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the Board) of Precision Drilling Corporation (Precision) announced today that, as part of its long-standing succession...

CALGARY, Alberta, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2025 third quarter results after the market closes on Wednesday, October 22,...

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients...

CALGARY, Alberta, Sept. 11, 2025 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure...

Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union1New seven-year data from the LADDER study...

PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...

Garage doors play a vital role in transforming and shaping the home's curb appeal, value, and character.

Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3...